

Carbon Reduction Plan

Supplier name:GSK.....

Publication date: ..24th April 2026.....

Commitment to achieving Net Zero

GSK is committed to achieving Net Zero emissions by **2045**.

Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

Baseline Year: 2020	
Additional Details relating to the Baseline Emissions calculations.	
Historic baseline year emissions from 2020 onwards were restated in 2023 following the demerger of GSK's Consumer Healthcare business to form Haleon in July 2022. The restatement excludes historic emissions that were allocated to the consumer healthcare business unit.	
Baseline year emissions:	
EMISSIONS	TOTAL (tCO₂e)
Scope 1	710,529
Scope 2	168,854
Scope 3 (Included Sources listed below)	9,949,039
1. Purchased Goods and Services	3,267,365
2. Capital Goods	162,372
3. Fuel and Energy Related Activities	88,797
4. Upstream Transportation	267,099
5. Waste Generated in Operations	20,033
6. Business Travel	41,748
7. Employee Commuting	36,856

9. Downstream Transportation and Logistics	135,185
11. Use of Sold Products	5,836,160
12. End-of-Life Treatment of Sold Products	23,533
15. Equity & Investments	69,891
Total Emissions	10,828,422

Current Emissions Reporting

Reporting Year: 2025	
EMISSIONS	TOTAL (tCO ₂ e)
Scope 1	479,000 (based on 2025 data)
Scope 2	7,000 (based on 2025 data)
Scope 3 (Included Sources listed below)	8,385,000 (the latest data available for scope 3 is based on 2024 activity)
1. Purchased Goods and Services	2,827,000
2. Capital Goods	227,000
3. Fuel and Energy Related Activities	75,000
4. Upstream Transportation	304,000
5. Waste Generated in Operations	31,000
6. Business Travel	133,000
7. Employee Commuting	60,000
9. Downstream Transportation and Logistics	29,000
11. Use of Sold Products	4,627,000
12. End-of-Life Treatment of Sold Products	46,000
15. Equity & Investments	26,000
Total Emissions	8,871,000

Emissions reduction targets

In 2023, The Science Based Targets initiative (SBTi) approved GSK's net zero target for 2045 in line with its Corporate Net-Zero Standard, the world's only framework for corporate net zero target setting in line with climate science. This commitment applies for both GSK and ViiV operations.

Near term target

GSK and ViiV commits to disclose and reduce absolute scope 1 & 2 (market approach) by 80% and scope 3 GHG emissions from Purchased goods and services, Fuel & Energy Related Activities, Upstream transportation and distribution, Waste Generated in Operations, Business travel, Employee commuting, Use of sold products and End-of-life treatment of sold products by 80% by 2030 from a 2020 base year. GSK discloses against Downstream Transportation and distribution but those categories are currently excluded from the target due to data improvement needs. GSK does, however, continue to maximise the transition from air to sea freight across its portfolio, and to collaborate with its peers to improve container load and procurement of sustainable fuels for the sector.


In line with GSK's reporting cycle, operational data (Scope 1 and 2) is readily available for 2025. For Scope 3, further reconciliation of emissions associated with cost of goods is required, therefore reported using figures from the previous fiscal year (which are externally audited annually). We are working with strategic data partners to improve agility in Scope 3 reporting in the future.

Long term target

GSK and ViiV commit to reduce absolute scope 1 & 2 (market approach) by 90% and scope 3 GHG emissions from Purchased goods and services, Capital goods, Fuel & Energy Related Activities, Upstream transportation and distribution, Waste Generated in Operations, Business travel, Employee commuting, Use of sold products and End-of-life treatment of sold products and investments by 90% by 2045 from a 2020 base year.

Our value chain carbon footprint

We have mapped our carbon footprint across our value chain to ensure we have a clear understanding of where to focus our efforts, which informs our pathway to net zero.



March 2026

(Infographic numbers show GSK and ViiV footprint across scopes 1,2 and 3 using 2024 numbers).

Our pathway to net zero

The graph below shows our projected carbon reduction pathway to 2030 and 2045 across the different parts of our carbon footprint, along with our planned carbon credits.



March 2026

Carbon Reduction Projects (applicable for both GSK and ViiV)


Completed Carbon Reduction Initiatives

In 2025, we reduced our Scope 1 and 2 carbon emissions by 14% compared with 2024, and by 45% compared with our 2020 baseline. This year we achieved our 2025 target to transition 100% of imported electricity to renewable sources. Scope 3 emissions are 16% lower than our baseline year of 2020, falling by 7% between 2023-24

In 2025, key factors in our reduced Scope 1 and 2 carbon emissions were switching to renewable electricity at our Singapore facilities, installing onsite renewable electricity generation at five sites and investment in process efficiencies.

GSK's carbon reduction initiatives addressing emissions across scopes 1, 2 and 3 are shown in the graphic below:

Priority actions to reduce emissions



Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard¹ and uses the appropriate Government emission conversion factors for greenhouse gas company reporting².

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard³.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

Signed on behalf of the Supplier:

Neale Belson

Electronically signed by: Neale Belson
Reason: I am signing for the reasons as stated in the document.
Date: Apr 16, 2026 11:16:23 GMT+1

Julie Guest

Electronically signed by: Julie Guest
Reason: I am signing for the reasons as stated in the document.
Date: Apr 20, 2026 18:00:19 GMT+1

Neale Neale Belson, SVP and General Manager, GSK UK

Julie Guest, General Manager, ViiV UK

¹ <https://ghgprotocol.org/corporate-standard>

² <https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting>

³ <https://ghgprotocol.org/standards/scope-3-standard>

